Attenuation of scopolamine-induced deficits in navigational memory performance in rats by bis(7)-tacrine, a novel dimeric AChE inhibitor

Acta Pharmacologica Sinica

Volumn 20, Issue 3, 1999, Pages 211-217

  Wang, Hong ^a   Carlier, Paul R ^a   Ho, Wing Lok ^a   Lee, Nelson Tze Kin ^a   Pang, Yuan Ping ^b   Han, Yi Fan ^a  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^b MAYO CLINIC CANCER CENTER   (United States)

Author keywords

Alzheimer disease; Bis (7) tacrine; Cholinesterase inhibitors; Memory; Morris water maze; Scopolamine; Tacrine

Indexed keywords

1,7 N HEPTYLENE BIS 9,9' AMINO 1,2,3,4 TETRAHYDROACRIDINE; SCOPOLAMINE; TACRINE; TACRINE DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; DOSE RESPONSE; DRUG EFFECT; MALE; MAZE TEST; MEMORY CONSOLIDATION; NONHUMAN; RAT; RECALL; SPATIAL MEMORY;

ANIMALS; CHOLINESTERASE INHIBITORS; MALE; MAZE LEARNING; MEMORY; RATS; RATS, SPRAGUE-DAWLEY; SCOPOLAMINE; TACRINE;

EID: 13044286787     PISSN: 02539756     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Marx J. Searching for drugs that combat Alzheimer's. Science 1996; 273: 50-3.
2. Robbins TW, McAlonan G, Muir JL, Everitt BJ. Cognitive enhancers in theory and practice: studies of the cholinergic hypothesis of cognitive deficits in Alzheimer's disease. Behav Brain Res 1997; 83: 15-23.
3. Bodick NC, Offen WW, Shannon HE, Satterwhite J, Lucas R, van Lier R, et al. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Alzheimer Dis Assoc Disord 1997; 11 Suppl 4: S16-22.
4. Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 1986; 315: 1241-5.
5. Lou G, Montgomery PR, Sitar DS. Bioavailability and pharmacokinetic disposition of tacrine in elderly patients with Alzheimer's disease. J Psychiatry Neurosci 1996; 21: 334-9.
6. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. J Am Med Assoc 1994; 271: 992-8.
7. Pang YP, Quiram P, Jelacic T, Hong F, Brimijoin S. Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. J Biol Chem 1996; 271: 23646-9.
8. Carlier PR, Han YF, Chow ESH, Li CPL, Wang H, Lieu TX, et al. Evaluation of short-tether bis-tacrine AChE inhibitors: A further test of the dual binding site hypothesis. Bioorg Med Chem 1999; 7: in press.
9. Wang H, Ho WL, Lee NTK, Carlier PR, Pang YP, Han YF. Comparison of the anticholinesterase effects of bistacrine and tacrine in vitro and in vivo. Soc Neurosci Abstr 1998; 24 (Pt 1): 184.
10. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984; 11: 47-60.
11. Bymaster FP, Heath I, Hendrix JC, Shannon HE. Comparative behavioral and neurochemical activities of cholinergic antagonists in rats. J Pharmacol Exp Ther 1993; 267: 16-24.
12. Riekkinen P Jr, Sirviö J, Aaltonen M, Riekkinen P. Effects of concurrent manipulations of nicotinic and muscarinic receptors on spatial and passive avoidance learning. Pharmacol Biochem Behav 1990; 37: 405-10.
13. Gattu M, Boss KL, Terry AV Jr, Buccafusco JJ. Reversal of scopolamine-induced deficits in navigational memory performance by the seed oil of Celastrus paniculatus. Pharmacol Biochem Behav 1997; 57: 793-9.
14. Cheng DH, Ren H, Tang XC. Huperzine A, a novel promising acetylcholinesterase inhibitor. Neuroreport 1996; 8: 97-101.
15. Palmer AM. Neurochemical studies of Alzheimer disease. Neurodegeneration 1996; 5: 381-91.
16. Schellenberg GD. Genetic dissection of Alzheimer disease, a heterogeneous disorder. Proc Natl Acad Sci USA 1995; 92: 8552-9.
17. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patient with Alzheimer's disease. J Am Med Assoc 1994; 271: 985-91.